公开(公告)号：WO9963972A9

公开(公告)日：2000-10-12

申请号：PCT/US9912772

申请日：1999-06-08

Applicant: DELSYS PHARMACEUTICAL CORP ,  CHEN JEN CHI ,  CHRAI SUGGY S ,  DESAI NITIN VITHALBHAI ,  HAMMER LAWRENCE HARRISON ,  KELLER DAVID ,  KUMAR NALIN ,  LAL PRINCE ,  LEVINE AARON WILLIAM ,  MURARI RAMASWAMY ,  MARA KERRY DENNIS O ,  POLINIAK EUGENE SAMUEL ,  RIVENBURG HOWARD CHRISTOPHER ,  ROACH WILLIAM RONALD ,  ROSATI DOMINIC STEPHEN ,  SINGH BAWA ,  SOUTHGATE PETER DAVID ,  SUN HOI CHEONG ,  ZANZUCCHI PETER JOHN

Inventor： CHEN JEN-CHI ,  CHRAI SUGGY S ,  DESAI NITIN VITHALBHAI ,  HAMMER LAWRENCE HARRISON ,  KELLER DAVID ,  KUMAR NALIN ,  LAL PRINCE ,  LEVINE AARON WILLIAM ,  MURARI RAMASWAMY ,  O'MARA KERRY DENNIS ,  POLINIAK EUGENE SAMUEL ,  RIVENBURG HOWARD CHRISTOPHER ,  ROACH WILLIAM RONALD ,  ROSATI DOMINIC STEPHEN ,  SINGH BAWA ,  SOUTHGATE PETER DAVID ,  SUN HOI CHEONG ,  ZANZUCCHI PETER JOHN

IPC: A61K9/14 ,  A61J1/03 ,  A61J3/00 ,  A61K9/16 ,  A61K9/51 ,  A61K9/70 ,  B05B5/025 ,  B05B5/08 ,  B05B5/16 ,  B65B1/04 ,  B65B1/30 ,  B65B11/50

CPC classification number: A61K9/70 ,  A61J1/035 ,  A61J3/00 ,  B05B5/08 ,  B65B1/04 ,  B65B1/30 ,  B65B11/50

Abstract: The present invention provides a product (1) that includes a pharmaceutical unit dosage or diagnostic form (6) that includes at least one active ingredient that is present in an amount that advantageously does not vary by more than about five percent from a predetermined target amount. In one embodiment, the unit form comprises a substrate (8), a deposit (14) that is disposed on the substrate and a cover layer (9) that overlies the deposit and is joined to the substrate by a bond that encircles that deposit, thereby encapsulating it between the substrate and cover substrates. The deposit comprises a powder, at least some of which includes the at least one active ingredient. The unit form is created via a dry powder deposition apparatus that electrostatically deposits the powder on the substrate utilizing an electrostatic chuck and charged powder delivery apparatus.

Abstract translation: 本发明提供了一种产品（1），其包括药物单位剂量或诊断形式（6），其包含至少一种活性成分，其有效量不超过预定目标量的约5％ 。 在一个实施例中，单元形式包括衬底（8），设置在衬底上的沉积物（14）和覆盖在沉积物上的覆盖层（9），并且通过围绕该沉积物的键与衬底接合， 从而将其封装在基板和盖基板之间。 沉积物包含粉末，其中至少一些包括至少一种活性成分。 单元形式通过干粉沉积设备产生，其使用静电卡盘和带电粉末输送装置将粉末静电沉积在基底上。

公开(公告)号：WO0173431A3

公开(公告)日：2002-07-04

申请号：PCT/US0107311

申请日：2001-03-06

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： LOEWY ZVI ,  MATTHIES DENNIS LEE

IPC: G01N33/50 ,  A61J1/03 ,  A61J3/00 ,  A61K9/22 ,  A61K9/52 ,  A61K9/70 ,  B05B5/08 ,  B65B1/04 ,  B65B1/30 ,  B65B11/50 ,  G01N33/52 ,  G01N33/543

CPC classification number: A61J3/00 ,  A61J1/035 ,  A61K9/70 ,  B05B5/08 ,  B65B1/04 ,  B65B1/30 ,  B65B11/50 ,  G01N33/521 ,  G01N33/54386

Abstract: The present invention provides an integrated structural unit that includes a diagnostic form that includes at least one active ingredient that is present in an amount that advantageously does not vary by more than about five percent from a predetermined target amount. In one embodiment, the unit form comprises a substrate, a deposit that is disposed on the substrate, and a spreading layer that overlies the deposit and is used to retain and spread a sample of liquid which is to be assayed. The deposit comprises a powder, including the active ingredient(s). The diagnostic form is created via a dry powder deposition apparatus that electrostatically deposits the powder on the substrate utilizing an electrostatic chuck and charged powder delivery apparatus.

Abstract translation: 本发明提供了一种综合结构单元，其包括诊断形式，其包括至少一种活性成分，所述活性成分的存在量有利地不超过预定目标量的约5％。 在一个实施例中，单元形式包括衬底，设置在衬底上的沉积物和覆盖在沉积物上并用于保留和铺展待测定的液体样品的铺展层。 沉积物包含包含活性成分的粉末。 通过使用静电卡盘和带电粉末输送装置将粉末静电沉积在基底上的干粉沉积装置产生诊断形式。

公开(公告)号：WO0137783A3

公开(公告)日：2001-12-27

申请号：PCT/US0042084

申请日：2000-11-10

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： O'MARA KERRY DENNIS ,  KELLER DAVID ,  MCGINN JOSEPH THOMAS

IPC: B65G53/58 ,  A61K9/14 ,  B05B5/025 ,  B05B5/03 ,  B05B5/043 ,  B05B5/047 ,  B05B5/08 ,  B05B5/16 ,  B65G53/44 ,  B05B5/04

CPC classification number: B05B5/032 ,  B05B5/043 ,  B05B5/047 ,  B05B5/08 ,  B05B5/1683 ,  Y10S239/07 ,  Y10T137/2076 ,  Y10T137/2273

Abstract: A diffuser (518) comprises a conduit having a cross-sectional area that increases in a direction fluid flow. In one embodiment, the diffuser is used to reduce the incidence and severity of flow fluctuations that occur in an electrostatic deposition apparatus. In some embodiments, the diffuser includes one or more flow control features. A first flow-control feature comprises one or more appropriately-shaped annular slits (520) through which fluid having a greater momentum than a primary fluid moving through the diffuser is injected into the "boundary layer" near the wall of the diffuser. A second flow control feature comprises one or more annular slits (548) or, alternatively, slots or holes that are disposed at appropriate locations around the circumference of the diffuser through which a portion of fluid flowing in the boundary layer is removed. Boundary-layer flow removal is effected, in one embodiment, by creating a pressure differential across such annular slit or slots. Among other benefits, such flow control features reduce any tendencies for flow separation of the primary fluid in the diffuser.

Abstract translation: 扩散器（518）包括具有沿流体流动方向增加的横截面积的导管。 在一个实施例中，扩散器用于减少在静电沉积设备中发生的流动波动的发生率和严重性。 在一些实施例中，扩散器包括一个或多个流量控制特征。 第一流量控制特征包括一个或多个适当形状的环形狭缝（520），具有比通过扩散器移动的主要流体更大动量的流体通过该狭缝被注入到扩散器壁附近的“边界层”中。 第二流动控制特征包括一个或多个环形狭缝（548）或可选地设置在围绕扩散器的圆周的适当位置处的狭缝或孔，通过该狭缝或狭孔移除在边界层中流动的一部分流体。 在一个实施例中，通过在这样的环形狭缝或多个狭缝之间产生压差实现边界层流动移除。 除了其它益处之外，这种流量控制特征减少了扩散器中主流体的流动分离的任何倾向。

公开(公告)号：WO0213762A3

公开(公告)日：2002-05-16

申请号：PCT/US0124949

申请日：2001-08-09

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： MURARI RAMASWAMY ,  CHRAI SUGGY S ,  CHEN JEN-CHI ,  KATDARE ASHOK ,  PARRY GREGORY E ,  KARETNY MARC S

IPC: A61K9/20 ,  A61K9/70 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A01N25/08 ,  A01N25/34 ,  A61K9/00 ,  A61K9/14 ,  A61K9/46 ,  A61K9/50 ,  B65D73/00 ,  B65D85/42

CPC classification number: A61K9/2086 ,  A61K9/2095 ,  A61K9/7007

Abstract: A novel solid pharmaceutical dosage formulation of hydrophobic drugs is disclosed, which provides enhanced dissolution and improved bioavailability. The hydrophobic drug is deposited electrostatically on the base substrate. The dosage form may include any pharmaceutically acceptable additive, disposed within a carrier that is segregated from, but in contact with, the deposit. Figure No. 1 depicts an isometric view of a product comprising a strip package containing a plurality of unit forms in accordance with the prior art.

Abstract translation: 公开了一种新型的疏水药物的固体药物剂型，其提供增强的溶解和改善的生物利用度。 疏水药物静电沉积在基底上。 剂型可以包括任何药学上可接受的添加剂，其被放置在与沉积物隔离但与沉积物接触的载体内。 图1示出了包括根据现有技术的包含多个单元形式的带状包装的产品的等距视图。

公开(公告)号：WO0018370A3

公开(公告)日：2000-07-20

申请号：PCT/US9921752

申请日：1999-09-22

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： CHRAI SUGGY S ,  MURARI RAMASWAMY

IPC: A61J3/00 ,  A61K9/00 ,  A61K9/08 ,  A61K9/20 ,  A61K45/00 ,  A61K47/32 ,  A61K47/36 ,  A61K47/38 ,  A61K47/42 ,  A61K9/10

CPC classification number: A61K9/2086 ,  A61K9/0056

Abstract: A liquid pharmaceutical for oral delivery wherein at the time of use, a solid unit dosage form is added to the liquid wherein the unit dosage form is comprised of a substrate soluble in the liquid and a particulate pharmaceutically active material in a pharmaceutically effective amount. At the time of use, the unit dosage form is added to the liquid, without requiring measurement of the liquid, and the entire liquid is consumed to provide for oral delivery of the pharmaceutically effective amount of material.

Abstract translation: 一种用于口服递送的液体药物，其中在使用时将固体单位剂型加入到液体中，其中单位剂型由可溶于液体的底物和药学有效量的颗粒状药物活性物质组成。 在使用时，将单位剂型添加到液体中，而不需要测量液体，并且消耗整个液体以提供药学有效量的材料的口服递送。

公开(公告)号：WO0203914A3

公开(公告)日：2002-06-06

申请号：PCT/US0121422

申请日：2001-07-06

Applicant: DELSYS PHARMACEUTICAL CORP ,  MURARI RAMASWAMY ,  CHRAI SUGGY S

Inventor： MURARI RAMASWAMY ,  CHRAI SUGGY S

IPC: A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K9/58 ,  A61K9/70 ,  A61K31/198 ,  A61K38/23 ,  A61K47/30 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/42 ,  A61P5/14 ,  A61K31/195

CPC classification number: A61K9/2095 ,  A61K9/2086 ,  A61K31/198

Abstract: A method is disclosed for formulating a solid dosage of thyroid hormone, while avoiding instability caused by interaction of the active ingredient with excipients. The thyroid hormone may be levothyroxine sodium or triiodothyronine. The method comprises depositing the active ingredient, preferably electrostatically, as a dry powder substantially free of excipients, onto a pharmaceutically acceptable polymer substrate. Solid pharmaceutical dosage forms also are disclosed.

Abstract translation: 公开了一种配制固体剂量的甲状腺激素，同时避免由活性成分与赋形剂相互作用引起的不稳定性的方法。 甲状腺激素可能是左旋甲状腺素钠或三碘甲状腺氨酸。 该方法包括将活性成分（优选静电地）以基本上不含赋形剂的干粉形式沉积到药学上可接受的聚合物基质上。 也公开了固体药物剂型。

公开(公告)号：EP0840631A4

公开(公告)日：2001-01-31

申请号：EP96928793

申请日：1996-07-25

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： DATTA PABITRA ,  DESAI NITIN V

IPC: A61M15/00 ,  A61M15/02 ,  B05B5/047 ,  B05B5/16 ,  A61J3/00

CPC classification number: B05B5/047 ,  A61M15/0045 ,  A61M15/02 ,  B05B5/1683

Abstract: A tribo-inhaler (100) having a container portion (104) for electrostatically retaining a predefined dose of medicament powder and extracting the medicament powder by inhaling air through the container portion.

公开(公告)号：EP1248595A4

公开(公告)日：2006-06-14

申请号：EP01904967

申请日：2001-01-22

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： KUPPERPBLATT GARY B ,  KARETNY MARC S ,  MURARI RAMASWAMY ,  CHRAI SUGGY S

IPC: A61K9/00 ,  A61K9/22 ,  A61K9/24 ,  A61K9/48 ,  A61K31/403 ,  A61K31/522 ,  A61P1/04 ,  A61P1/08 ,  A61P11/00 ,  A61P11/06 ,  A61P11/08 ,  A61P25/00 ,  A61P25/06 ,  A61K9/14 ,  A61K9/20

CPC classification number: A61K9/4808 ,  A61K9/209

Abstract: Controlled release, multi-step drug dosage forms comprising a plurality of dose units and a plurality of separators that control release of drug from the dose units. In one embodiment, a dose unit is a single dosage amount of a drug that is electrostatically deposited onto a substrate. The dosage forms are designed to deliver a drug to exhibit a desired pharmacokinetic profile.

公开(公告)号：EP1210760A4

公开(公告)日：2003-05-21

申请号：EP00974094

申请日：2000-09-11

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： SUN HOI CHEONG ,  SINGH BAWA ,  RIVENBURG HOWARD CHRISTOPHER

IPC: H02N13/00 ,  H02N1/00

CPC classification number: B82Y15/00 ,  B01J2219/00468 ,  B01J2219/005 ,  H02N1/004

Abstract: A charged particle (Bead) is moved from a first electrode (9) to a second electrode (10) also with the aid of a guide electrode (Guide Electrode).

公开(公告)号：EP1121752A4

公开(公告)日：2003-05-21

申请号：EP99953173

申请日：1999-10-14

Applicant: DELSYS PHARMACEUTICAL CORP

Inventor： SUN HOI CHEONG ,  DESAI NITIN V ,  ROACH WILLIAM R ,  LUDINGTON DAVID N ,  PLETCHER TIMOTHY A ,  KELLER DAVID ,  LANG FRANK B ,  SOUTHGATE PETER D ,  MCGINN JOSEPH T

IPC: H01L21/683 ,  H02N13/00

CPC classification number: H01L21/6833 ,  H02N13/00

Abstract: Provided is an electrostatic sensing chuck for attracting particles to a portion of a particle contact surface near a deposition electrode, the electrostatic sensing chuck comprising a pixel comprising: a deposition electrode (DE) for selectively establishing an attraction field (Ea) at the particle contact surface; a shield electrode (SE) oppositely biased with respect to the deposition electrode; a charge sensing circuit to measure charge accumulated on each of the deposition electrode and the shield electrode, wherein the charge sensing circuit subtracts a second charge it senses at the shield electrode from a first charge it senses at the deposition electrode, thereby determining accumulated charge at the deposition electrode balanced by accumulated charge at the shield electrode.